Phambili: Moving forward without the blindfold

摘要

In The Lancet Infectious Diseases , Glenda Gray and colleagues 1 report long-term follow-up results of the HVTN 503 or Phambili (which means “moving forward” in the Xhosa language) phase 2b efficacy trial of the Merck adenovirus type 5 (Ad5)-vectored DNA vaccine encoding HIV-1 subtype B gag, pol, and nef proteins. Phambili recruited South African participants at high risk of heterosexually transmitted HIV infection (subtype C); however, vaccinations were stopped during the enrolment phase after rele